











































Clinical experience with the AKT1 inhibitor miransertib in two
children with PIK3CA-related overgrowth syndrome
Citation for published version:
Forde, K, Resta, N, Ranieri, C, Rea, D, Kubassova, O, Hinton, M, Andrews, KA, Semple, RK, Irvine, AD &
Dvorakova, V 2021, 'Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-
related overgrowth syndrome', Orphanet journal of rare diseases. https://doi.org/10.1186/s13023-021-
01745-0
Digital Object Identifier (DOI):
10.1186/s13023-021-01745-0
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Orphanet journal of rare diseases
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
Forde et al. Orphanet J Rare Dis          (2021) 16:109  
https://doi.org/10.1186/s13023-021-01745-0
RESEARCH
Clinical experience with the AKT1 inhibitor 
miransertib in two children with PIK3CA-related 
overgrowth syndrome
Karina Forde1, Nicoletta Resta2, Carlotta Ranieri2, David Rea3, Olga Kubassova4, Mark Hinton4, 
Katrina A. Andrews5,6, Robert Semple5,7, Alan D. Irvine1,8*  and Veronika Dvorakova1
Abstract 
Background: PIK3CA-related overgrowth spectrum (PROS) refers to a group of rare disorders, caused by somatic 
activating mutations in PIK3CA, resulting in abnormal PI3K-AKT-mTOR pathway signalling. Significant associated 
morbidity is frequently observed, and approved treatments are lacking. Miransertib (ARQ 092) is a novel, orally avail-
able, selective pan-AKT inhibitor with proven in vitro efficacy. Following recent results of the use of AKT inhibitors in 
Proteus syndrome (PS) and AKT-mutant cancers, we investigated its therapeutic use in two patients with severe PROS 
who had exhausted conventional treatment methods.
Results: Two patients, one with CLOVES variant (P1) and one with facial infiltrating lipomatosis and hemimegalen-
cephaly (P2), were commenced on miransertib treatment on a compassionate use basis. In patient one, intra-abdom-
inal and paraspinal overgrowth had resulted in respiratory compromise, obstructive uropathy, dysfunctional seating 
and lying postures, and chronic pain. In patient two, hemifacial overgrowth and hemimegalencephaly had caused 
difficulties with articulation and oral function, and refractory epilepsy. Miransertib treatment was continued for a 
median duration of 22 months (range 22–28). In patient one, alleviation of respiratory compromise was observed and 
functionally, seating and lying postures improved. Serial volumetric MRI analysis revealed 15% reduction in calcu-
lated volumes of fatty overgrowth between treatment commencement and end. In patient two, reduction in seizure 
burden and improved parent-reported quality of life measures were reported. Treatment was discontinued in both 
patients due to lack of sustained response, and poor compliance in year two of treatment (P2). No significant toxicities 
were reported.
Conclusion: We report the first paediatric case series of the use of miransertib in two children with PROS. Objective 
clinical response was observed in patient one, and improvement in key qualitative outcomes was reported in patient 
two. Treatment was well tolerated with no significant toxicities reported. This case series highlights the potential ther-
apeutic utility of miransertib in selected paediatric patients with severe PROS, and further demonstrates the potential 
for re-purposing targeted therapies for the treatment of rare diseases. An open label, Phase 1/2 study of miransertib in 
children with PROS and PS is underway to more accurately assess the efficacy of miransertib in the treatment of PROS 
disorder (NCT03094832).
Keywords: PIK3CA-related overgrowth spectrum (PROS), Miransertib, AKT inhibitor, Next generation sequencing 
(NGS), Targeted treatment
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Background
PIK3CA-related overgrowth spectrum (PROS) refers to 
a group of heterogeneous, rare disorders characterised 
by segmental progressive overgrowth, caused by somatic 
activating mutations in phosphatidylinositol-4 5-bispho-
sphate 3-kinase catalytic subunit alpha (PIK3CA) gene 
[1]. The PI3K/AKT/mTOR pathway is essential for nor-
mal cellular functions including growth, metabolism, and 
proliferation. PIK3CA encodes the p110alpha subunit 
of phosphoinositide 3-kinase that converts phosphati-
dylinositol 3,4-bisphosphate to phosphatidylinositol 
3,4,5-triphosphate. Subsequent activation of AKT and 
mTOR signalling results in promotion of tissue growth. 
Dysregulation causing over-activation of the pathway 
results in increased cellular metabolism, angiogenesis 
and reduction in cellular apoptosis [2].
In recent years, next generation sequencing (NGS) has 
significantly expanded the understanding of the molecu-
lar aetiology of overgrowth syndromes [1, 3–6]. In 2014, 
the identification of PIK3CA mutations in a group of 
patients with heterogeneous, but overlapping, clinical 
features [7] resulted in the subsequent development of 
diagnostic criteria for the newly termed PIK3CA-related 
overgrowth spectrum (PROS) [1]. These disorders are 
extremely rare, although the exact prevalence is difficult 
to estimate owing to the phenotypic heterogeneity of dis-
orders and variability of correct clinical diagnoses to date 
[8].
PIK3CA-related overgrowth spectrum (PROS) dis-
orders are associated with significant morbidity and 
mortality. Past therapeutic approaches centred around 
symptomatic surgical or medical management of associ-
ated complications, with minimal success. There are no 
approved targeted medical treatments.
The P13K/AKT/mTOR pathway is recognised as one 
of the most frequently dysregulated pathways in human 
cancers, with PIK3CA identified as the most commonly 
mutated proto-oncogene in somatic cancer [9]. With the 
advent of increasing knowledge regarding the oncogenic 
implications associated with dysregulation of the P13K/
AKT/mTOR pathway, the development of several small 
molecules targeting different key components of the 
pathway have come under clinical investigation. Thus, 
opportunities for targeted treatment of overgrowth dis-
orders are now being recognised.
The mTOR inhibitor sirolimus has been used with par-
tial success in overgrowth disorders. A previous open 
label multicentre study reported a modest mean reduc-
tion in total tissue volume at affected sites (7.2%) in 23/30 
patients who were evaluable after 26  weeks treatment. 
Treatment was associated with a high rate of adverse 
events, many severe, resulting in consequent treatment 
withdrawal in a significant number (7/39; 18%) [10]. In 
addition, a previous study of its use in children with het-
erogeneous complex vascular disorders appeared to show 
greatest response rates in those with lymphatic malfor-
mations [11]. Furthermore, since sirolimus fails to effec-
tively inhibit mTORC2, feedback activation of PI3K and 
AKT persists, rendering it a less attractive option in the 
long-term management of patients with PROS. The focus 
for future therapeutic options has expanded to include 
AKT inhibitors, PI3K inhibitors and dual PI3K-mTOR 
inhibitors, many of which are undergoing investigation in 
oncology trials [12]. More recently, Venot et al. reported 
a substantial clinical response in 19 patientswith PROS 
treated with the PI3K inhibitor alpelisib (BYL719), in an 
open label, non-RCT case series, along with a favourable 
safety profile [9], further supporting the repurposing of 
agents targeting the P13K/AKT/mTOR in the treatment 
of PROS.
Miransertib (ARQ 092) is a novel, orally available, 
highly selective pan-AKT inhibitor with proven in  vitro 
efficacy [13]. Lindhurst et al.previously identified a reduc-
tion in AKT phosphorylation and downstream targets 
in cells of patients with Proteus syndrome treated with 
miransertib [14]. A subsequent phase 0/1 study of miran-
sertib in six patients with Proteus syndrome showed a 
50% reduction in pAKT phosphorylation in affected tis-
sues in 5/6 participants four months after treatment 
initiation [15]. Subsequently, Leoni et  al. reported the 
successful treatment of a patient with Proteus syndrome 
and relapsed low-grade serous ovarian carcinoma with 
miransertib, who demonstrated partial response on 
computed tomography (CT) imaging at 24  weeks, and 
achieved complete remission after 22  months of treat-
ment, along with significant reported improvement in 
quality of life scores [16].
Methods
Aims
To investigate the therapeutic use of pan-AKT inhibitor 
miransertib (ARQ 092) in two paediatric patients with 
severe PIK3CA-related overgrowth spectrum disorder, 




Patient one was a 16  years old female with Congeni-
tal Lipomatous Overgrowth, Vascular malformations, 
Epidermal nevi, Scoliosis/Skeletal/Spinal anomalies 
(CLOVES) phenotype [17, 18]. She was born to non-con-
sanguineous parents with a birth weight of 2.89 kg (50th 
centile) and occipitofrontal circumference of 31.6  cm 
(10th centile) and was noted to have a large posterior 
thoracic wall lipoma and large feet with splayed toes at 
Page 3 of 7Forde et al. Orphanet J Rare Dis          (2021) 16:109  
birth. Subsequent musculoskeletal examination identified 
a dislocated right hip and bilateral talipes equinovarus. 
Progressive intra-abdominal and paraspinal lipomatous 
overgrowth created significant difficulties with mobil-
ity and seating; these were treated with debulking pro-
cedures and liposuction during the first 10 years of life. 
While these procedures lead to partial but temporary 
improvement, the lipomatous lesions regrew within 
12  months. Despite repeated orthopaedic intervention, 
she developed progressive lower limb discrepancy and 
subsequent flexed deformity of the right lower limb, 
resulting in loss of function.
At the age of four, she presented with a urinary tract 
infection and was found to have marked bladder wall 
thickening and irregularity on ultrasound suggestive of 
neuropathic bladder, along with bilateral hydronephro-
sis. Functional studies demonstrated focal scarring of 
the right kidney. Urodynamics confirmed a large, atonic 
bladder with incomplete voiding. Chronic renal fail-
ure, with estimated function 50% of normal range first 
became evident aged seven. Due to anterior displacement 
of the bladder by progressive infiltrative lipomatous over-
growth, an obstructive uropathy component also devel-
oped, requiring placement of a suprapubic catheter.
By the age of thirteen, she was completely wheelchair 
bound and had frequent hospital admissions for recur-
rent urinary tract infections. Chronic pain became a 
severely disabling problem, and her progressive intra-
abdominal overgrowth resulted in difficulties with lying 
and seating. She was treated with mTOR inhibitor siroli-
mus aged fifteen for a period of 12  months. Sub-thera-
peutic troughs were observed despite incremental dosing 
increases, and treatment was stopped after one year due 
to progression of her disease.
Progressive respiratory compromise from diaphragm 
elevation caused by intra-abdominal lipomatous over-
growth, and relentless flank pain from massive lipo-
matous distension determined the urgency of further 
treatment. Surgical therapeutic approaches were not 
favoured due to the infiltrative nature of fatty overgrowth 
encasing vital structures in the retroperitoneum, thus 
necessitating investigation of novel medical therapeutic 
approaches.
Patient two
Patient two was a five years old male with PROS-asso-
ciated facial infiltrating lipomatosis and hemimegalen-
cephaly phenotype. He was born to non-consanguineous 
parents at term by elective Caesarian section for unstable 
lie with a birth weight of 4.15 kg (75th centile) and occip-
itofrontal circumference of 40.3  cm (> 99.6th centile). 
On examination he was noted to have right hemifacial 
macrosomia but no other signs of hemi-hypertrophy. His 
neonatal course was complicated by focal onset seizures 
day seven of life, characterised by right occipital dis-
charges on electroencephalogram. Magnetic resonance 
imaging of the brain at three months reported right hem-
imegalencephaly and polymicrogyria of the parietal lobe 
with cortical thickening and malformation, particularly 
in the occipital lobe (Fig. 1).
During the first few years of life, profound hemifacial 
and soft tissue and skeletal overgrowth began to affect 
the oral commissure on the right side, and hemi-mac-
roglossia and macrodontia caused progressive difficulties 
with articulation and oral function. Magnetic resonance 
imaging (MRI) showed extensive fatty hypertrophy and 
infiltration of the right side of the face, including the 
tongue and facial musculature (Fig.  2). Repeated lipo-
suction and excision of excess tissue was undertaken for 
debulking and symmetrisation with a therapeutic aim 
of improving function. However progressive bony over-
growth was also evident which was deemed impossible to 
correct until skeletal maturation was reached. Executive 
functioning difficulties became apparent, consistent with 
right hemisphere abnormalities, reflected by attention 
and behavioural dysregulation difficulties. Additional 
educational support was also required due to low average 
scores obtained in general verbal and non-verbal skills on 
neuropsychological assessments.
He was commenced on sirolimus aged five for a 
period of eight months and achieved therapeutic levels 
of 5–10  ng/ml, but ongoing progression of his disease 
resulted in early discontinuation of treatment. Increased 
seizure frequency and an emerging subtle left-sided 
Fig. 1 MRI at 2 weeks of age showing right hemimegalencephaly 
and polymicrogyria of the parietal lobe (patient two)
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motor deficit in addition to relentless hemifacial over-
growth despite multiple surgical interventions rendered 
further consideration of targeted medical treatment 
important.
Molecular investigations
Molecular investigations were undertaken in both 
patients to help guide therapeutic approaches. In patient 
one, studies of dermal fibroblasts cultured from an 
affected area revealed that levels the level of phospho-
rylation of AKT at serine 473, a downstream marker of 
PI3K, were 7 times higher than those in healthy controls, 
as determined by ELISA of a cellular lysate. Activation 
of the PI3K/AKT/MTOR pathway was assessed by assay 
of  phosphorylation of AKT at residue p.Ser473 using  a 
direct ELISA assay (InstantOne®,  eBioscience).  Early 
passage dermal fibroblasts cultured from were grown to 
90% confluence, then serum starved for 24 h  in DMEM 
containing 0.5% bovine serum albumin (Sigma). Cells 
were washed once in cold PBS, snap frozen in  liquid 
nitrogen and stored at − 80 °C. Frozen monolayers were 
scraped in 150uL cell  lysis buffer provided in the ELISA 
kit. Protein quantification was by DC Protein assay (Bio-
Rad) and lysates were diluted in lysis buffer to a protein 
concentration of 0.3–0.5  ng protein/µl  before assay per 
manufacturer’s instructions.  Briefly,  30–50  µg of  cell 
lysate was loaded onto the pre-coated ELISA plate with 
50  µl the primary  and secondary  antibody conjugates, 
and incubated for 1 h on a shaker. After washing, detec-
tion reagent was added, and was quenched with H2S04-
containing stop solution. Absorbance was measured at 
450 nm and results were normalized to the mean of five 
wild type control cell lines analysed at the same time. 
Analysis of patient cell ELISA scores (normalised to 
negative control cell scores) against  PIK3CA  genotype 
in a cohort of 118 people with segmental overgrowth 
who had undergone both cellular studies and deep gen-
otyping of fibroblast DNA previously revealed a signifi-
cant elevation of AKT-Ser473 phosphorylation in cells 
from patients with PIK3CA mutations versus cells from 
patients where no pathogenic  PIK3CA  mutation was 
found (p = 0.0098, Mann–Whitney U test).  Using the 
arbitrary cut-off of a ‘positive’ ELISA score as more than 
two standard deviations above the mean of the negative 
control distribution, this test had the power to predict a 
PIK3CA mutation with a positive predictive value of 58% 
and a negative predictive value of 70% in our hands.
Subsequent genetic analysis of affected tissue iden-
tified a hotspot mutation in PIK3CA (c.3140A > G; 
p.His1047Arg) with reported variant frequency 12%. In 
patient two, genetic testing of affected fibroblasts dem-
onstrated a different well established activating muta-
tion (c.1258T > C; p.Cys420Arg) in PIK3CA, with variant 
frequency 15%, confirming PIK3CA-related overgrowth 
spectrum disorder. The mutations were revealed by tar-
geted next generation sequencing (NGS) technology 
of genes involved in the P13K/AKT pathway and con-
firmed by Sanger sequencing. Next generation sequenc-
ing was carried out on Ion Torrent Personal Genome 
Machine (ThermoFisher Scientific, TFS), using the Ion 
PGM Sequencing Hi-Q 200 Kit (TFS) according to the 
manufacturer’s instructions (Loconte et  al. 2015). Data 
analysis was performed using the Torrent Suite Software 
v5.0.5 (TFS). Reads were aligned to the hg19 human ref-
erence genome from the UCSC Genome Browser (http://
genom e.ucsc.edu/) and to the BED file designed using 
Ion AmpliSeq Designer. Alignments were visually veri-
fied with the software Alamut® v2.8.0 (Interactive Bio 
software). Coverage and variant analysis were conducted 
according to methods previously reported by Loconte 
et al. [19].
Investigational treatment with miransertib (ARQ 092)
Due to the severe, progressive nature of overgrowth 
in both cases resulting in increasing morbidity, and 
the lack of alternative available approved treatments, 
the use of novel experimental therapies was investi-
gated. Applications for the compassionate use of the 
experimental drug, miransertib, were submitted to and 
approved by the Drugs and Therapeutics committee of 
Children’s Health Ireland, Crumlin (Dublin, Ireland); 
the Health Product Regulatory Agency of Ireland 
(HPRA) was informed of the orphan use of this drug 
and their adverse event reporting system was adhered 
to during the period of therapy. Initial dosing of 5 mg/
Fig. 2 MRI at 4 years demonstrating extensive fatty infiltration and 
hypertrophy of the right side of the face (patient two)
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m2/day was determined based on tolerability and effi-
cacy reports in a phase 1 clinical trial investigating the 
use of miransertib in adult and paediatric patients over 
12  years with PS [14]. ArQule Inc. (Burlington MA) 
provided miransertib on a managed patient access pro-
gramme basis for both patients.
Informed consent was obtained from the legal 
guardians of both patients prior to treatment com-
mencement. Baseline pre-treatment assessments were 
carried out, including evaluation of complete blood 
count, renal, liver, bone and fasting lipid profile and 
urinalysis. Transthoracic echo was undertaken to 
assess cardiac function. Volumetric MRI analysis of 
the targeted overgrowth area was also performed pre-
treatment and every three months thereafter.
Subsequent monitoring included weekly assessment 
for glycosuria and point of care testing for hypergly-
caemia. Evaluations of complete blood count, renal, 
liver and bone profile were repeated at week 4 and 
week 8 and every 8 weeks thereafter for the treatment 
duration. Adverse effects were classified according to 
the Common Terminology Criteria for Adverse Events, 
version 5.0 (CTCAE v.5.0) [19]. Where possible, serial 
volumetric analysis of DIXON MRI was carried out 
by a radiologist blinded to the patient’s medical his-
tory and visit schedule using Dynamika software 




Patient 1 commenced miransertib aged sixteen at a 
dose of 30  mg once daily and continued treatment for 
28 months. Over the course of her treatment, an improve-
ment in her respiratory compromise was observed, and 
functionally, she became able to lie flat. Her chronic renal 
failure was largely stable. Patient-reported quality of life 
measures improved.
Targeted regions of interest in MRI slices of the in-
phase images were identified to define areas of fatty over-
growth. By treatment end, a 15% decline in the calculated 
volume of fatty overgrowth from baseline imaging was 
observed (Fig. 3).
Treatment with miransertib was well tolerated with no 
significant toxicities other than hyperlipidaemia, compa-
rable to prior lipid profile derangement (grade 1 CTCAE 
v.5.0) with sirolimus therapy. Ultimately treatment was 
discontinued after 28 months due to poor patient adher-
ence in the second year of therapy and failure of sus-
tained beneficial effect, reflected by increased lipomatous 
volumes on MRI at 28 months.
Patient two
Patient two commenced miransertib 10 mg once daily at 
5 years of age, and continued treatment for 22 months. A 
subsequent reduction in seizure frequency was observed 
along with reported improved cognitive engagement 
in school and at home. Parental-reported quality of life 
measures, determined on clinical questioning at patient 
Fig. 3 MRI of pelvis showing highlighted regions of interest (ROI) on adjacent slices, pre-treatment (left) and post 24 months treatment (right) 
(patient one)
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visits, improved. Treatment was very well tolerated 
with no adverse effects apart from loose stools (grade 1 
CTCAE v.5.0), favourably comparable to that reported 
with previous sirolimus therapy. Objective assessment of 
response to treatment using volumetric MRI analysis was 
not possible due to ongoing surgical treatment of facial 
overgrowth during the treatment period.
Following discontinuation of miransertib treatment, 
both patients were commenced on targeted therapy 
with alpelisib (BYL719) based on the clinical efficacy in 
patients with PROS recently reported by Venot et al. [9]. 
Treatment is ongoing in both.
Discussion
Here, we report the first paediatric case series of the 
use of miransertib in two children with severe PIK3CA-
related overgrowth spectrum, one with CLOVES variant 
and one with facial infiltrating lipomatosis with hemi-
megalencephaly. The first patient demonstrated clear 
clinical improvement with observed stability in renal 
function and a 15% reduction in calculated volumes 
of fatty overgrowth at the targeted regions of interest. 
Functionally, improved lying and sitting postures were 
achieved, most importantly evidenced by the patient 
being able to lie flat again. These initial improvements 
were not sustained into the second year of therapy, largely 
due to poor treatment adherence, reflected objectively by 
increased lipomatous volumes on MRI at 28 months.
In the case of patient two, there was a significant 
improvement in parent- and patient-reported quality of 
life and function. Furthermore, a reduction in seizure 
burden on treatment was observed. Unfortunately, accu-
rate volumetric analysis using MRI could not be used to 
monitor response to treatment due to ongoing surgical 
intervention. Due to the experimental nature of miran-
sertib therapy, it was not deemed appropriate to defer any 
surgical treatments offered until response was evaluated. 
The use of miransertib did not preclude surgical treat-
ment and was safe to use in the pre- and post-operative 
period. Similarly, serial photography was not a useful tool 
in either case, due to the targeted intra-abdominal site 
of interest in case one, and due to surgical treatment in 
case two. Quality of life improvements were self-reported 
in both cases. Quantitative assessment of quality of life 
using standardised tools such as Peds QL [20] is recom-
mended in future studies.
The recently reported therapeutic utility of alpelisib 
(BYL719) in an open label case series (RCT data are 
awaited) of patients with PROS [9] demonstrates the 
potential availability of targeted therapies for patients 
with PROS. To date, we have observed a favourable 
safety profile in the sequential therapeutic use of miran-
sertib and alpelisib in these two paediatric patients with 
severe PROS, highlighting the future potential for per-
sonalised medical treatment in these patients.
Conclusion
The pan-AKT inhibitor miransertib (ARQ092) was well 
tolerated with no significant toxicities reported in two 
patients with severe PIK3CA-related overgrowth spec-
trum disorder. Treatment response and tolerability was 
superior to sirolimus in both cases. This case series 
highlights the potential therapeutic utility of miran-
sertib in selected paediatric patients with severe PROS. 
An open label, Phase 1/2 study of miransertib admin-
istered to subjects at least 2  years of age with PROS 
and Proteus syndrome (PS) is currently underway to 
more accurately assess the efficacy of miransertib in 
the treatment of PIK3CA-related overgrowth spectrum 
disorder [21].
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